LUPRON DEPOT POWDER FOR SUSPENSION, SUSTAINED-RELEASE

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

LEUPROLIDE ACETATE

제공처:

ABBVIE CORPORATION

ATC 코드:

L02AE02

INN (International Name):

LEUPRORELIN

복용량:

7.5MG

약제 형태:

POWDER FOR SUSPENSION, SUSTAINED-RELEASE

구성:

LEUPROLIDE ACETATE 7.5MG

관리 경로:

INTRAMUSCULAR

패키지 단위:

1

처방전 유형:

Prescription

치료 영역:

GONADOTROPINS

제품 요약:

Active ingredient group (AIG) number: 0116959002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2012-11-01

제품 특성 요약

_ _
_LUPRON DEPOT (leuprolide acetate) _
_Page 1 of 100 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LUPRON DEPOT®
leuprolide acetate for depot suspension
3.75 mg/syringe (1-Month slow release), 7.5 mg/syringe (1-Month slow
release),
11.25 mg/syringe (3-Month slow release), 22.5 mg/syringe (3-Month slow
release),
30 mg/syringe (4-Month slow release)
pre-filled dual-chamber syringe containing sterile lyophilized
microspheres intramuscular injection
Gonadotropin-releasing hormone analog (ATC: L02AE02)
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, QC H4S 1Z1
Date of Initial Authorization:
•
Central Precocious Puberty:
NOV 26, 1986
•
Prostate Cancer: MAR 11,
1999
•
Endometriosis: MAR 11, 1999
•
Uterine Fibroids: FEB 07,
2017
Date of Revision: MAR 19, 2024
Submission Control Number: 280431
_ _
_LUPRON DEPOT (leuprolide acetate) _
_Page 2 of 100 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, PROSTATE CANCER
POPULATION (Only)
01/2024
7 WARNINGS AND PRECAUTIONS, ALL POPULATIONS
03/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
5
1
INDICATIONS
...............................................................................................................
5
1.1
Pediatrics
................................................................................................................
6
1.2
Geriatrics
................................................................................................................
6
2
CONTRAINDICATIONS
.................................................................................................
6
3
SERIOUS WARNINGS A